TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2195.
Locate Jan Aushadhi KendraClinical Overview
Remogliflozin Etabonate (100 mg) is an oral prodrug of remogliflozin, a selective inhibitor of renal SGLT2. It blocks glucose reabsorption in proximal renal tubules, increasing urinary glucose excretion and improving glycemic control without stimulating insulin. Indicated for the treatment of type 2 diabetes mellitus in adults.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once or twice daily with water, with or without meals. Maintain good hydration.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Genital mycotic infections, increased urination, thirst, nausea. Rare/Severe: Diabetic ketoacidosis, urosepsis, and volume depletion.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Ensure adequate daily water intake. Hold prior to major surgeries. Practice proper genital hygiene.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Remogliflozin Etabonate 100mg + Vildagliptin 50mg Tablets
Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.
Remogliflozin Etabonate 100mg + Metformin Hydrochloride 1000mg Tablets
Metformin Hydrochloride and Remogliflozin Etabonate is a dual oral antidiabetic formulation. Remogliflozin is an ester prodrug of a selective SGLT2 inhibitor that promotes glycosuria via renal tubular filtration, while metformin controls basal hepatic glucose output. Indicated for glycemic control in adult patients with type 2 diabetes mellitus.
Remogliflozin Etabonate Tablets 100mg + Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride and Remogliflozin Etabonate is a dual oral antidiabetic formulation. Remogliflozin is an ester prodrug of a selective SGLT2 inhibitor that promotes glycosuria via renal tubular filtration, while metformin controls basal hepatic glucose output. Indicated for glycemic control in adult patients with type 2 diabetes mellitus.
Remogliflozin Etabonate 100mg + Teneligliptin 10mg Tablets
Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.